WO1997045592A1 - Schallschutzeinrichtung für gleise - Google Patents

Schallschutzeinrichtung für gleise Download PDF

Info

Publication number
WO1997045592A1
WO1997045592A1 PCT/AT1997/000109 AT9700109W WO9745592A1 WO 1997045592 A1 WO1997045592 A1 WO 1997045592A1 AT 9700109 W AT9700109 W AT 9700109W WO 9745592 A1 WO9745592 A1 WO 9745592A1
Authority
WO
WIPO (PCT)
Prior art keywords
plate
plates
partial
soundproofing device
support sections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AT1997/000109
Other languages
German (de)
English (en)
French (fr)
Inventor
Bernhard Neumann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gmundner Fertigteile GmbH and Co KG
Original Assignee
Gmundner Fertigteile GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT93496A external-priority patent/AT403809B/de
Priority claimed from AT0101596A external-priority patent/AT405426B/de
Priority to AT97922748T priority Critical patent/ATE229595T1/de
Priority to SI9730491T priority patent/SI0901536T1/xx
Priority to EP97922748A priority patent/EP0901536B1/de
Priority to US09/194,505 priority patent/US6253872B1/en
Priority to AU28801/97A priority patent/AU738889B2/en
Priority to DE59708955T priority patent/DE59708955D1/de
Application filed by Gmundner Fertigteile GmbH and Co KG filed Critical Gmundner Fertigteile GmbH and Co KG
Priority to JP54125697A priority patent/JP3822641B2/ja
Priority to CA002255946A priority patent/CA2255946C/en
Priority to DK97922748T priority patent/DK0901536T3/da
Priority to HU9903612A priority patent/HU221872B1/hu
Publication of WO1997045592A1 publication Critical patent/WO1997045592A1/de
Anticipated expiration legal-status Critical
Priority to NO19985600A priority patent/NO316078B1/no
Ceased legal-status Critical Current

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E01—CONSTRUCTION OF ROADS, RAILWAYS, OR BRIDGES
    • E01B—PERMANENT WAY; PERMANENT-WAY TOOLS; MACHINES FOR MAKING RAILWAYS OF ALL KINDS
    • E01B19/00—Protection of permanent way against development of dust or against the effect of wind, sun, frost, or corrosion; Means to reduce development of noise
    • E01B19/003—Means for reducing the development or propagation of noise

Definitions

  • the invention relates to a soundproofing device for tracks, with sound-absorbing plates mounted on the rails of the track, which are supported on the rails by elastic profiles, the plates arranged between the rails cantilevering the space between the rails. Furthermore, the invention relates to sound-absorbing panels for such a soundproofing device.
  • the plates arranged between the rails of the track consist of three layers or layers which are supported by elastic profiles on the rail foot, web and on the underside.
  • the upper layer consists of steel wire fabric that can be walked on, the edge of which is glued, welded or vulcanized into the profile.
  • the middle layer is designed as a sound absorption layer and consists of glass wool or rock wool. This sound absorption layer lies on the lower layer, which is designed as a perforated wall or grate and is supported in a recess in the profile in the region of the rail foot.
  • the panels are also arranged on the outside of the rail and angled upward at the ends in order to form a lateral soundproofing wall.
  • Such mineral wool panels have adequate sound absorption at high frequencies, but have inadequate sound absorption at low frequencies.
  • a further disadvantage of this construction is that the walkable perforated wall made of steel wire mesh can detach itself from its anchoring in the profiles at higher and repeated loads, so that the sound absorption layer underneath can be damaged.
  • the dust penetrating through the perforated wall can be deposited on the upper side of the sound absorption layer and thus the sound damping effect can deteriorate increasingly.
  • the invention has for its object to provide a soundproofing device for tracks with sound-absorbing plates, which has good sound absorption or damping over the entire frequency range essential for the sound level of rail traffic, with a permanent mechanical Strength of the device should be guaranteed.
  • the soundproofing device of the type mentioned at the outset in that the plates consist of particles of porous lightweight construction material which are joined together with a binder, and in that the plates have embedded reinforcement and are arranged uncovered.
  • the airborne noise emanating in particular from the wheels of a rail vehicle and from the rails is absorbed on the surface of the plates by the pores of the particles and can also be selected if a structure is left that leaves fine spaces between the particles, via spaces or channels between the particles penetrate deeper into the plate to gradually be completely dampened there.
  • the reinforcement of the panels also ensures that they can be walked on.
  • the top of the plates is structured, and even better results can be achieved if the structuring is irregular.
  • the top of the plates is preferably provided with ribs running parallel to the rails, which results in structuring that is simple to construct.
  • the ribs have a trapezoidal cross-section, since this makes it easier to absorb obliquely incident sound waves.
  • the wall of the cavity resonators and their sound openings are provided with a sound-absorbing structure, and / or if the wall of the cavity resonators and their tubular sound openings are provided with a sound-absorbing layer are provided.
  • the cavities forming the cavity resonators are designed to be open at the bottom and are covered with a lower plate.
  • the cavities forming the cavity resonators are designed to be open at the bottom and form a resonance cavity together with the track bedding.
  • the damped resonance frequency of the cavity resonators is within a frequency range from 150 to 1000 Hz, preferably between 500 and 1000 Hz.
  • a special embodiment is also provided in which the installation and removal of the plates to be provided between the two rails of a track can be accomplished in a very simple manner.
  • This embodiment of the soundproofing device is characterized in that the space lying between the two rails of a track is bridged with partial plates arranged in pairs, each of which engages with at least one supporting rib in the link chambers of the rails, the partial plates of each pair of plates at their mutually facing edges are supported on one another and in this case support sections and support sections are provided alternately in a meandering manner on each section plate along the edge facing the other section plate, the support sections being formed by depressions extending from the top of the plate and facing the other section plate and under the support sections from the underside of the plate, upward depressions are formed, which are complementary to the depressions of the support sections, and the support sections of a partial plate on the support sections the other partial plate and the support sections of the other partial plate rest on the supporting sections of the one partial plate.
  • the zones of the partial plates of each pair of plates to be joined in an articulated manner can simply be plugged together when the partial plates are unfolded, after which the partial plates can be inserted between the rails without problems by leveling the pair of plates, and the partial plates also become Loads not pushed apart.
  • a preferred type of the last-mentioned embodiment which is characterized in that projections and recesses shaped complementarily to the projections, into which the projections engage, are provided on those surfaces on which the partial plates of a pair of plates abut one another, for mutual locking of the partial plates, offers the advantage that the cohesion of the partial plates of a pair of plates is ensured even over very long periods of time even when unfavorable vibrations act on the partial plates.
  • Such a crowning can be formed on a partial plate by a surface section which extends from the edge facing the other partial plate of the pair of plates and extends away from the underside of the plate, and a subsequent surface section which approaches the underside of the plate. If one wishes to additionally provide a latching in such a configuration of the partial plates, it is advantageous if they are designed in such a way that projections pointing downward are provided on the end edges of the supporting sections and recesses complementary to these projections are provided on the supporting surfaces of the supporting sections.
  • An embodiment which is particularly favorable for the course of the leveling process when installing the partial plates and for achieving the most stable possible position of the two partial plates of a pair of plates relative to one another in the installed state characterized in that the cambered shaped wings are shaped according to a toothing which, up to the leveled position of the partial plates of the respective pair of plates, enables sliding or rolling movement of the facing wings and supporting surfaces towards one another and in the leveled position of these partial plates against one another Movement of these partial plates to each other blocks.
  • the reinforcement provided in the sub-panels extends over the panel surface and engages in the supporting sections and in the supporting sections and in the supporting ribs. It is also advantageous if one provides that an elastic or / or shock-absorbing insert or coating is provided between the wings provided on the support sections and the support surfaces provided on the support sections.
  • a sound-absorbing plate according to the invention is characterized in that the plate consists of particles made of porous lightweight material, which are joined together with a binder, that the plate has an embedded reinforcement, and that in the plate cavity resonators with a large area of the Plate directed tubular sound openings are formed, which large area to form the top is provided when installing the plate in the track. It is advantageous here if the cavities forming the cavity resonators are designed to be open and widening towards the large area that lies on the side of the plate facing away from the tubular sound openings. A further development is characterized in that the cavities forming the cavity resonators are covered with a lower plate on the side facing away from the tubular sound openings.
  • Embodiments of a plate designed according to the invention which are provided for the aforementioned formation with partial plates to be joined to form a pair of plates, are characterized in that the plate consists of particles of porous lightweight building material, which are joined together with a binder, so that the plate is an embedded one Reinforcement has that the plate is provided on one edge side with a support rib for engaging in the tab chambers of rails and on the edge side opposite this support rib has meandering succession of support sections and support sections, the support sections extending from the top of the plate and depressions extending to the edge are formed and under the support sections, from the underside of the plate, upward depressions are formed, which are complementary to the depressions of the support sections.
  • cavity resonators are formed in the plate with tubular sound openings directed towards a large area of the plate, which large area is provided for forming the upper side when the plate is installed in the track. It is also advantageous here if the reinforcement provided in the plate extends over the entire surface of the plate and extends into the support sections and into the support sections and into the support rib. If desired, the plates or partial plates can also be provided with a frame running along the edge, preferably consisting of metal or fiber-reinforced plastic.
  • FIG. 1 shows a plan view of a track with sound-absorbing plates arranged between the rails
  • FIG. 2 shows a section along the line II-II in Fig.l
  • 3 shows an embodiment of a plate in cross section
  • FIG. 4 shows an enlarged detail of the surface of the plate according to FIG. 2 or 3;
  • FIG. 5 shows an embodiment of a soundproofing device designed according to the invention with partial plates in a top view
  • FIG. 10 shows a variant with regard to the design of the support sections and the support sections in a sectional representation corresponding to FIG. 7,
  • FIG. 11 shows another embodiment of a soundproofing device designed according to the invention with partial panels, in a top view
  • FIG. 16 shows a variant with regard to the design of the support sections and the support sections of the partial plates in a sectional representation corresponding to FIG. 13.
  • sound-absorbing plates 3 are arranged next to one another in the longitudinal direction of the track between the rails 2.
  • the generally rectangular plates 3 have, on their two edges along the rails 2, projecting support ribs 4, which are interposed with elastic profiles 5, for example made of rubber or elastomer, support on the rail base 6, on the rail web 7 and on the underside of the rail head 8 of the rails 2.
  • the plates 3, the surface of which is shown enlarged in FIG. 4, consist of particles 9 made of porous lightweight material, which are joined together with a suitable binder.
  • Plastic granulate, granular or spherical and fired alumina particles, granular slag particles, or similar fired natural or artificially produced materials are used as the lightweight construction material, these particles being selectively connected with a suitable plastic binder or cement, so that small spaces or channels 10 remain, which allow air ducting and drainage of penetrating rain or melt water.
  • the panels 3 are provided with a reinforcement 11, for example made of steel or other metals, fiber-reinforced plastic, glass fiber mats or the like.
  • the surface of the plates 3 can be increased by structuring.
  • the top 12 of the plates 3 can be provided with ribs 13 which run parallel to the rails 2 and are spaced apart from one another and which, as shown in FIG. 3, have a trapezoidal cross section and a height a above the rail head 8 which are closed ⁇ not exceeding 5 cm.
  • the structure can also be irregular, for example by increasing or decreasing the spacing of the ribs 13 from one another.
  • a structuring of the top 12 for example, truncated cones, truncated pyramids, cylinders, cuboids, etc. can also be provided, which are arranged either at the same or at different distances from one another.
  • 3 cavity resonators 14 in the manner of the Helmholz resonator are formed in the plates, the tubular sound openings of which 15 are provided on the top 12 of the plates 3.
  • the cavities forming the cavity resonators 14 are frustoconical and open at the bottom, the openings formed thereby being covered by a sub-plate 16, for example glued to the plate 3, in order to form the cavity resonator 14 .
  • the cavities forming the cavity resonators 14 can also be designed to deviate from the shape of a truncated cone, for example spherical, cylindrical, pyramid-shaped, etc., in order to achieve a different frequency behavior in the case of sound absorption.
  • the volumes of the cavity resonators 14 and the dimensions of the tubular sound openings can be varied in order to achieve the desired frequency behavior or frequency absorption spectrum. As shown in FIG.
  • the tubular sound openings 15 open perpendicular to the top 12 of the plate 3.
  • the tubular sound openings 15 can also open at an angle to the top 12 of the plates 3 in order to be able to better absorb obliquely incident sound waves .
  • the plates 3 with the cavity resonators 14 can be produced in a rectangular shape in which positive shapes of the cavity resonators with attached pipe pieces for the sound openings are used, whereupon the mold is filled with the particles 9 and a binder and demolded after the binder has hardened becomes.
  • Prefabricated cavity resonators with attached pipe pieces as sound openings can also be used as positive forms, which either consist of a suitable sound-absorbing material or are provided on the inside with a layer of sound-absorbing material.
  • sound-absorbing plates with cavity resonators can also be provided on the outside of the rails 2.
  • the plate 18 shown in dash-dotted lines on the right rail 2 is at one End, similar to the plate 3 lying between rails 2, is supported on the rail 2 via an elastic profile 5 and at the other end via an elastic strip 19 and fixed by means of a fastening element, in particular a screw 20.
  • the plate 21 on the left rail 2, also shown with a dash-dotted line, is supported and fixed in the same way as the plate 18, but has an end region that is angled upwards on the outside in order to form a soundproofing wall.
  • the two plates 18, 21 likewise have reinforcement (not shown) and, if appropriate, a structure in the form of ribs (not shown). If desired, the plates can also be provided with a frame running along the edge.
  • the space 22 lying between the two rails 2 of a track 1 is filled or bridged with paired sound-absorbing partial plates 3a, 3b.
  • These sub-plates 3a, 3b have support ribs 4 which engage in the tab chambers 23 of the rails 2, and elastic profiles 5 with an approximately C-shaped cross section are inserted between the support ribs 4 and the rails 2.
  • the partial plates 3a, 3b are supported with their supporting ribs 4 on the rail foot 6 and laterally against the rail web 7 and held upwards by engagement under the rail head 8.
  • the partial plates 3a, 3b bridge the distance 24 between the rails 2 in a self-supporting manner.
  • a plurality of support ribs 4 are provided on each of the partial plates 3a, 3b, which are arranged at a distance from one another in order to leave the fastening elements 25 provided for the rails 2 accessible.
  • each pair of plates are supported on one another, so that each pair of plates forms an assembled body which bridges the distance 24 between the rails 2 in a self-supporting manner.
  • the support sections 28 being formed by depressions 30 which extend from the top side 12 of the plate and extend to the edge facing the other partial plate; under the support sections 29, starting from the lower side 31 of the plate, upward depressions 32 are formed, and the support sections of the partial plate 3a lie on the supporting sections of the partial plate 3b and the supporting sections of the partial plate 3b rest on the supporting sections of the partial plate 3a;
  • the depressions 30 are complementary to the depressions 32, so that the support surfaces 34 formed on the support sections 29 by the depressions 32 lie substantially snugly on the support surfaces 33 formed by the depressions 30 on the support sections 28.
  • the partial plates 3a, 3b In order to insert the partial plates 3a, 3b in pairs between the rails 2 of a track, they can first be arranged in the unfolded position, as shown in FIG. 9, and in the process they can be inserted into one another with their meandering edges 26, 27 also arranges the elastic profiles 5, which have a C-shaped cross section, between the supporting ribs 4 of the partial plates 3a, 3b and the rails 2. Then the partial plates 3a, 3b are pivoted or folded down, as indicated by the arrow 35, until they assume the leveled position shown in FIGS. 5 to 7, in which the partial plates 3a, 3b of each pair of plates space 22 between bridge the rails 2 in a self-supporting manner.
  • the support surfaces 33 provided in the support sections 28 have a cambered shape, and there is such a cambered shape also in the support surfaces 34 provided on the support sections 29, and this cambered shape of the named surfaces ensures that the partial plates retain their shape 3a, 3b create ge, which in the leveled position of the partial plates 3a, 3b inhibits a mutual movement of these partial plates in the direction of the plate plane (arrows 36).
  • projections 37 are provided on the support surfaces 34 and recesses 38 are provided on the support surfaces 33, which are complementary to the projections 37; in the leveled position of the partial plates, the Projections 37 into the recesses 38, so that there is a mutual locking of the partial plates 3a, 3b.
  • an elastic and / or shock-absorbing insert or coating can be provided between the support surfaces 33 and the support surfaces 34.
  • the supporting surfaces 33 provided on the supporting sections run, starting from the edge 26 or 27 of the respective partial plate 3a or 3b, first rising steeply from the underside 31 of the plate and then becoming flatter, which is advantageous for joining the partial plates to the pairs of plates. From a geometrical point of view, it is favorable if such domed wings are shaped according to a toothing which, up to the leveled position of the partial plates 3a, 3b of the respective plate pair, enables a sliding movement or rolling movement of the mutually facing wings and supporting surfaces on one another, and in the leveled position (Fig. 5 to 7) locks these partial plates against movement to each other.
  • This geometrical shape corresponding to a toothing can extend up to the top 12 of the plate.
  • the projections 37 can, as shown in FIGS. 5 to 8, be provided on the end edges 39 of the support sections 29, which can bring advantages when joining the partial plates, but it is also possible to place such projections 37 elsewhere, e.g. slightly removed from the edge of the support surfaces.
  • the support surfaces 33 and the support surfaces 34 are largely flat; In this case, too, recesses 38, into which projections 37 engage, are provided for mutual locking of the partial plates 3a, 3b.
  • the two partial plates 3a, 3b of a pair of plates lie on one another in a meandering manner on the underside 31 of the plate, so that the mutually facing edges of the partial plates 3a , 3b run on the underside of the plate following a meandering line 43. This results in a very intimate cohesion of the partial plates 3a, 3b forming a pair of plates.
  • the partial plates 3a, 3b are rounded at the mutually facing edges 26, 27 from the underside 31 of the plate upwards, the radius of curvature of this rounding being equal to or smaller than the distance 41 between the edges 26, 27 and the rail-side edges 42 of the partial plates 3a, 3b. This measure is also advantageous for an unrestrained process of inserting the partial plates.
  • the reinforcement 11 provided in the partial plates extends over the entire surface extent of the partial plates 3a, 3b and, as indicated by the broken lines in FIG. 8, both in the support sections 28 and in the support sections 29 as well engages in the support ribs 4.
  • cavity resonators 14 with sound openings 15 can be provided, as is the case e.g. 11 to 14 is shown.
  • the plates can also be provided with frames 44, as is e.g. is indicated by dashed lines in FIG.

Landscapes

  • Architecture (AREA)
  • Civil Engineering (AREA)
  • Structural Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Building Environments (AREA)
  • Soundproofing, Sound Blocking, And Sound Damping (AREA)
  • Railway Tracks (AREA)
  • Devices Affording Protection Of Roads Or Walls For Sound Insulation (AREA)
  • Power-Operated Mechanisms For Wings (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Signal Processing Not Specific To The Method Of Recording And Reproducing (AREA)
  • Noise Elimination (AREA)
  • Magnetic Heads (AREA)
  • Bridges Or Land Bridges (AREA)
  • Holo Graphy (AREA)
PCT/AT1997/000109 1996-05-29 1997-05-23 Schallschutzeinrichtung für gleise Ceased WO1997045592A1 (de)

Priority Applications (11)

Application Number Priority Date Filing Date Title
DK97922748T DK0901536T3 (da) 1996-05-29 1997-05-23 Støjdæmpningsindretning til spor
HU9903612A HU221872B1 (hu) 1996-05-29 1997-05-23 Zajvédelmi berendezés vasúti vágányokhoz
JP54125697A JP3822641B2 (ja) 1996-05-29 1997-05-23 軌道用の防音装置
EP97922748A EP0901536B1 (de) 1996-05-29 1997-05-23 Schallschutzeinrichtung für gleise
US09/194,505 US6253872B1 (en) 1996-05-29 1997-05-23 Track soundproofing arrangement
AU28801/97A AU738889B2 (en) 1996-05-29 1997-05-23 A noise control device for tracks
DE59708955T DE59708955D1 (de) 1996-05-29 1997-05-23 Schallschutzeinrichtung für gleise
AT97922748T ATE229595T1 (de) 1996-05-29 1997-05-23 Schallschutzeinrichtung für gleise
SI9730491T SI0901536T1 (en) 1996-05-29 1997-05-23 Track soundproofing arrangement
CA002255946A CA2255946C (en) 1996-05-29 1997-05-23 Track soundproofing arrangement
NO19985600A NO316078B1 (no) 1996-05-29 1998-11-30 Lydisoleringsanordning for skinnespor, samt en lydabsorberende plate for denne

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AT93496A AT403809B (de) 1996-05-29 1996-05-29 Schallschutzeinrichtung für gleise
ATA934/96 1996-05-29
ATA1015/96 1996-06-11
AT0101596A AT405426B (de) 1996-06-11 1996-06-11 Schienengleiche eindeckung für gleise

Publications (1)

Publication Number Publication Date
WO1997045592A1 true WO1997045592A1 (de) 1997-12-04

Family

ID=25594370

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT1997/000109 Ceased WO1997045592A1 (de) 1996-05-29 1997-05-23 Schallschutzeinrichtung für gleise

Country Status (14)

Country Link
US (1) US6253872B1 (enExample)
EP (1) EP0901536B1 (enExample)
JP (1) JP3822641B2 (enExample)
CN (1) CN100424268C (enExample)
AT (1) ATE229595T1 (enExample)
AU (1) AU738889B2 (enExample)
CA (1) CA2255946C (enExample)
DE (1) DE59708955D1 (enExample)
DK (1) DK0901536T3 (enExample)
ES (1) ES2186891T3 (enExample)
HU (1) HU221872B1 (enExample)
NO (1) NO316078B1 (enExample)
TW (1) TW345603B (enExample)
WO (1) WO1997045592A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0945547A1 (de) * 1998-03-21 1999-09-29 Johann Rath Vorrichtung zur Dämpfung von Schallemissionen an Gleisanlagen
EP1039032A1 (de) * 1999-03-26 2000-09-27 DVG Deutsche Verpackungsmittel-GmbH Absorptionsbelag zur Reduzierung der Schallabstrahlung für Gleiskörper
US6481637B1 (en) * 2000-11-20 2002-11-19 Mcqueen Philip Jeffrey Rail pad and method for strain attentuation
WO2005085529A1 (de) * 2004-03-05 2005-09-15 Gmundner Fertigteile Gesellschaft M.B.H. & Co. Kg. Störschall mindernde gleiseindeckung
NL2003697C2 (nl) * 2009-10-22 2011-04-26 Univ Twente Weg met geluid-diffractoren.

Families Citing this family (301)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
DE10111919A1 (de) * 2001-03-13 2002-09-19 Boegl Max Bauunternehmung Gmbh Fahrwegträger
HU224236B1 (hu) * 2001-12-14 2005-06-28 Attila Szebeni Vasúti acélhidaknál alkalmazható, egymáshoz csatlakoztatott elemekbõl álló, zaj- és rezgéscsökkentett mûanyag járólemezrendszer
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
AU2003248747A1 (en) 2002-06-27 2004-01-19 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
EP1606291A2 (en) 2002-07-02 2005-12-21 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its dervatives
AT6414U1 (de) * 2002-07-17 2003-10-27 Gmundner Fertigteile Gmbh Gleisabdeckung
GB2399123B (en) * 2003-03-05 2006-03-01 Corus Uk Ltd Rail damper
WO2004099158A1 (en) * 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. Monocyclic diazodioxide based bcl-2 protein antagonists
WO2004099162A1 (en) * 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. Polycyclic diazodioxide-based bcl-2 protein antagonist
WO2004110350A2 (en) * 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
US20100331380A1 (en) * 2009-06-29 2010-12-30 Esposito Luke A Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
WO2005090370A1 (en) * 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US20100126797A1 (en) * 2004-02-12 2010-05-27 Humphries Eric C Panel Assembly For Traffic Noise Barrier Wall
US8616331B2 (en) 2004-02-12 2013-12-31 Eric C. Humphries Panel assembly for traffic noise barrier wall
US7546900B2 (en) * 2004-02-12 2009-06-16 Evonik Cyro Llc Panel assembly for traffic noise barrier wall
WO2005113523A1 (en) 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
CA2580767A1 (en) 2004-09-17 2006-03-30 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
US20060067889A1 (en) * 2004-09-27 2006-03-30 Light Sciences Corporation Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents
US20070131480A1 (en) * 2004-12-06 2007-06-14 Corbin Maxwell H Jr Sound arresting barrier
US7464791B2 (en) * 2005-01-27 2008-12-16 Pretty Products, Llc Acoustic mats and methods for making the same
US20060230699A1 (en) * 2005-03-22 2006-10-19 Keene James R Sound control flooring systems and methods therefor
WO2006130217A2 (en) * 2005-04-01 2006-12-07 The Regents Of The University Of California Substituted phosphate esters of nucleoside phosphonates
EP1866319B1 (en) 2005-04-01 2011-11-23 The Regents of The University of California Phosphono-pent-2-en-1-yl nucleosides and analogs
WO2008051197A2 (en) * 2005-09-20 2008-05-02 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US8138361B2 (en) * 2005-12-28 2012-03-20 The Trustees Of The University Of Pennsylvania C-10 carbamates of taxanes
WO2007106537A2 (en) * 2006-03-13 2007-09-20 Activx Biosciences, Inc. Aminoquinolones as gsk-3 inhibitors
EA200870385A1 (ru) * 2006-03-29 2009-04-28 Фолдркс Фармасьютикалз, Инк. Ингибирование токсичности альфа-синуклеина
EP2032409A1 (en) * 2006-06-13 2009-03-11 Newstyle Nominees PTY LTD Rail track crossing
EP2484696B1 (en) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistic hLIGHT-specific human monoclonal antibodies
CA2664152C (en) 2006-09-21 2014-09-30 Activx Biosciences, Inc. Serine hydrolase inhibitors
BRPI0715579A2 (pt) 2006-10-19 2015-05-26 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
JP5013590B2 (ja) * 2006-11-14 2012-08-29 エンデバーハウス株式会社 伸縮性に優れた線路用吸音材
AU2007333667A1 (en) 2006-12-19 2008-06-26 Auspex Pharmaceuticals, Inc. Preperation and utility of CCR5 inhibitors
WO2008079371A1 (en) * 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
AU2008219622A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
LT2125698T (lt) 2007-03-15 2016-10-10 Auspex Pharmaceuticals, Inc. Deuterintas d9-venlafaksinas
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
EP2170062A4 (en) * 2007-07-12 2010-12-29 Tragara Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES
WO2009035634A2 (en) * 2007-09-11 2009-03-19 Activx Biosciences, Inc. Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
CN101855229A (zh) 2007-09-12 2010-10-06 埃迪威克斯生物科学公司 作为gsk-3抑制剂的螺环状氨基喹诺酮
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
WO2009059512A1 (en) * 2007-11-07 2009-05-14 Wai Lun Ho Tunable vibration absorbing device
WO2009066152A2 (en) 2007-11-21 2009-05-28 Pharmaxis Ltd. Haloallylamine inhibitors of ssao/vap-1 and uses therefor
WO2009111611A2 (en) * 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
KR101713501B1 (ko) 2008-03-17 2017-03-07 암비트 바이오사이언시즈 코포레이션 Ｒａｆ 키나아제 조절제로서의 퀴나졸린 유도체 및 그의 사용방법
US20120034155A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
CN101658533A (zh) * 2008-08-29 2010-03-03 首都医科大学宣武医院 抗肿瘤药物的干细胞递送
US8048204B2 (en) * 2008-09-23 2011-11-01 Rwdi Air Inc. Wall assembly
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
RU2529019C2 (ru) 2009-02-27 2014-09-27 Эмбит Байосайенсиз Корпорейшн Модулирующие jak киназу хиназолиновые производные и способы их применения
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
US8146310B2 (en) * 2009-03-11 2012-04-03 Keene Building Products Co., Inc. Noise control flooring system
KR101748891B1 (ko) * 2009-03-11 2017-06-19 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ-3 억제제로서의 7-시클로알킬아미노퀴놀론
MX2011009413A (es) 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
JP5766177B2 (ja) 2009-03-27 2015-08-19 ベトディーシー，インコーポレイテッド ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
BRPI1014669A2 (pt) 2009-04-22 2017-07-18 Axikin Pharmaceuticals Inc antagonistas ccr3 de arilsulfonamida 2,5-dissubstituída
NZ620048A (en) 2009-04-22 2015-07-31 Axikin Pharmaceuticals Inc 2,5-disubstituted arylsulfonamide ccr3 antagonists
KR20120034627A (ko) 2009-04-22 2012-04-12 액시킨 파마수티컬스 인코포레이티드 아릴설폰아마이드 ｃｃｒ3 길항제
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
EP2532659A1 (en) 2009-07-07 2012-12-12 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
DK2451435T4 (da) 2009-07-08 2022-02-28 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Natriumthiosulfat-indeholdende farmaceutiske sammensætninger
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
CN102470127A (zh) 2009-08-19 2012-05-23 埃姆比特生物科学公司 联芳基化合物和其使用方法
US8470817B2 (en) * 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
US8871460B2 (en) 2009-11-09 2014-10-28 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
US8528286B2 (en) * 2009-11-10 2013-09-10 Keene Building Products Co., Inc. Sound control mat
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
CA2784748A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
SG181896A1 (en) * 2009-12-23 2012-07-30 Map Pharmaceuticals Inc Novel ergoline analogs
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US8999995B2 (en) 2010-03-02 2015-04-07 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
US8741894B2 (en) 2010-03-17 2014-06-03 Axikin Pharmaceuticals, Inc. Arylsulfonamide CCR3 antagonists
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
US20130178503A1 (en) 2010-06-01 2013-07-11 Biotheryx Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
JP5844354B2 (ja) 2010-06-01 2016-01-13 ビオトヘルイク， インコーポレイテッド ヒドロキシピリドン誘導体、その医薬組成物、及び増殖性疾患治療のためのその治療的使用
EP2576532B1 (en) 2010-06-07 2018-07-18 Novomedix, LLC Furanyl compounds and the use thereof
US20130178522A1 (en) 2010-07-19 2013-07-11 James M. Jamison Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
JP5872558B2 (ja) 2010-09-01 2016-03-01 アムビト ビオスシエンセス コルポラチオン ピラゾリルアミノキナゾリンの臭化水素酸塩
US20130225615A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
EP2611809A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
EP2611796B1 (en) 2010-09-01 2016-04-20 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
WO2012030918A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
WO2012030912A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
CA2810024A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
EP2611794A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
EP2611812A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
US20130296363A1 (en) 2010-09-01 2013-11-07 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US20120088769A1 (en) 2010-10-11 2012-04-12 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
US20120125711A1 (en) * 2010-11-24 2012-05-24 Stahr Richard E Sound absorbing panel and system
EP3178465A1 (en) 2010-12-06 2017-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
EP2670396A1 (en) 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
BR112013024909A2 (pt) 2011-03-28 2019-09-24 Mei Pharma Inc composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k
EP2691388A1 (en) 2011-03-28 2014-02-05 MEI Pharma, Inc. (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
JP6042406B2 (ja) 2011-03-28 2016-12-14 メイ プハルマ，インコーポレーテッド （α−置換アラルキルアミノ及びヘテロアリールアルキルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、それらを含む医薬組成物、並びに増殖性疾患の治療で使用するためのこれらの化合物
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
RU2013158449A (ru) 2011-06-23 2015-07-27 Мэп Фармасьютикалс, Инк. Новые фторэрголиновые аналоги
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
IN2014CN03597A (enExample) 2011-10-14 2015-10-09 Ambit Biosciences Corp
EP2793580A4 (en) 2011-12-19 2015-05-20 Map Pharmaceuticals Inc NEW DERIVATIVES OF ISO-ERGOLINE
AU2012355983A1 (en) 2011-12-21 2015-01-22 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
SG11201405761WA (en) 2012-03-16 2014-10-30 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
CN104520268B (zh) 2012-05-02 2017-05-24 勃林格殷格翰国际有限公司 Ssao的取代的3‑卤代烯丙基胺抑制剂及其用途
EP2861562B1 (en) 2012-06-14 2018-05-09 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of stat3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
SG11201500489YA (en) 2012-07-25 2015-02-27 Kolltan Pharmaceuticals Inc Anti-kit antibodies and uses thereof
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
KR20150053906A (ko) 2012-09-07 2015-05-19 액시킨 파마수티컬스 인코포레이티드 동위원소 농축 아릴설폰아미드 ccr3 길항제
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
EP2916830A2 (en) 2012-11-08 2015-09-16 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
US9156781B2 (en) 2012-11-30 2015-10-13 Novomedix, Llc Substituted biaryl sulfonamides and the use thereof
US8895743B2 (en) 2012-12-21 2014-11-25 Map Pharmaceuticals, Inc. Methysergide derivatives
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
EP2943188A1 (en) 2013-01-11 2015-11-18 Mayo Foundation for Medical Education and Research Vitamins c and k for treating polycystic diseases
SG11201509982UA (enExample) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
WO2015005774A1 (en) * 2013-07-07 2015-01-15 4Silence B.V. Diffractor for diffracting sound
RU2016111675A (ru) 2013-08-30 2017-10-04 Эмбит Байосайенсиз Корпорейшн Соединения биарилацетамида и способы их применения
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015127351A1 (en) 2014-02-24 2015-08-27 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US10005765B2 (en) 2014-03-20 2018-06-26 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
US10202398B2 (en) 2014-03-20 2019-02-12 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
AU2015259471A1 (en) 2014-05-12 2016-11-24 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease with caspase inhibitors
SMT202100116T1 (it) 2014-05-28 2021-05-07 Agenus Inc Anticorpi anti-gitr e metodi di utilizzo degli stessi
WO2015195474A1 (en) 2014-06-18 2015-12-23 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
EP3179857B1 (en) 2014-08-14 2021-09-08 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
CN106999593A (zh) 2014-09-12 2017-08-01 妥必徕疗治公司 用于纤维化治疗的赛尼克韦罗组合疗法
EP3209658A1 (en) 2014-10-24 2017-08-30 Biogen MA Inc. Diterpenoid derivatives and methods of use thereof
WO2016106221A1 (en) 2014-12-22 2016-06-30 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
HUE049801T2 (hu) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopirazol kináz inhibitorok
BR112017015487A2 (pt) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc Composto; composição; método de tratamento e/ou prevenção de enxaqueca, als, doença de alzheimer, doença de parkinson, distúrbios extrapirimidais, depressão, náusea, êmese, síndrome das pernas inquietas, insônia, agressão, doença de huntington, doença cardiopulmonar, fibrogênese, hipertensão arterial pulmonar, ansiedade, dependências a drogas, distonia, parassonia ou hiperlactinemia em um indivíduo; métodos de agonização dos receptores d2, 5-ht1d, 5-ht1a e 5-ht2c, em um indivíduo; método de antagonização do receptor d3 em um indivíduo; métodos de agonização seletiva dos receptores 5 -ht1d, e 5-ht2c, método de fornecimento de atividade de antagonista funcional no receptor 5 -ht2b ou no receptor 5-ht7, ou em ambos, em um indivíduo; método de fornecimento de atividade de antagonista funcional nos receptores adrenérgicos em um indivíduo
WO2016119700A1 (en) 2015-01-28 2016-08-04 Jn Therapeutics Substituted imidazo [1, 2-a] pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
ES2937020T3 (es) 2015-03-03 2023-03-23 Kymab Ltd Anticuerpos, usos y métodos
CN107849144B (zh) 2015-05-29 2021-09-17 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
CN113713108A (zh) 2015-06-23 2021-11-30 纽罗克里生物科学有限公司 用于治疗神经学疾病或病症的vmat2抑制剂
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
LT3875459T (lt) 2015-10-30 2024-02-26 Neurocrine Biosciences, Inc. Valbenazino dihidrochlorido druskos ir jų polimorfai
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
EP4455145A3 (en) 2015-12-02 2025-03-12 Astraea Therapeutics, LLC Piperidinyl nociceptin receptor compounds
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CA3009169A1 (en) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
JP2019500397A (ja) 2015-12-31 2019-01-10 クオナトウス ファーマシューティカルズ，インコーポレイテッド カスパーゼ阻害剤を肝疾患の治療に使用する方法
KR20180099712A (ko) 2016-01-08 2018-09-05 셀진 코포레이션 항증식성 화합물, 및 이의 약제학적 조성물 및 용도
AU2017206039B2 (en) 2016-01-08 2021-03-25 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-N-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
JP2019510085A (ja) 2016-03-08 2019-04-11 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療のためのナノ粒子ならびに方法および化合物
JP2019513151A (ja) 2016-03-08 2019-05-23 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． カンプトテシン誘導体及びその使用
CN108884019A (zh) 2016-04-11 2018-11-23 克雷西奥生物科技有限公司 氘代氯胺酮衍生物
WO2017194789A1 (en) 2016-05-13 2017-11-16 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
MA45123A (fr) 2016-05-27 2019-04-10 Agenus Inc Anticorps anti-tim-3 et leurs méthodes d'utilisation
DE102016111064A1 (de) * 2016-06-16 2017-12-21 Vossloh-Werke Gmbh Elastisches Element für einen Befestigungspunkt für eine Schiene für Schienenfahrzeuge und Befestigungspunkt
CN106087611B (zh) * 2016-06-20 2019-07-12 勾厚渝 轨道交通构件
CA3030099A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
WO2018035281A1 (en) 2016-08-17 2018-02-22 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
MA46285A (fr) 2016-09-19 2019-07-31 Mei Pharma Inc Polythérapie
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR102539159B1 (ko) 2016-11-07 2023-06-02 주식회사 뉴라클사이언스 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
WO2018089427A1 (en) 2016-11-09 2018-05-17 Novomedix, Llc Nitrite salts of 1, 1-dimethylbiguanide, pharmaceutical compositions, and methods of use
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
US10799503B2 (en) 2016-12-01 2020-10-13 Ignyta, Inc. Methods for the treatment of cancer
JP2020500875A (ja) 2016-12-02 2020-01-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
FI3551660T3 (fi) 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
EP3551225A1 (en) 2016-12-07 2019-10-16 Agenus Inc. Antibodies and methods of use thereof
JP7090151B2 (ja) 2017-01-27 2022-06-23 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
NZ797281A (en) 2017-02-17 2025-10-31 Eidos Therapeutics Inc Processes for preparing ag-10, its intermediates, and salts thereof
JP7307681B2 (ja) 2017-02-17 2023-07-12 カムリス インターナショナル インコーポレイテッド 汎用性抗毒素
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
KR20190133198A (ko) 2017-03-27 2019-12-02 셀진 코포레이션 면역원성의 감소를 위한 방법 및 조성물
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc anticorpos anti-cd137 e métodos de uso dos mesmos
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
TW202402800A (zh) 2017-05-01 2024-01-16 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體類和使用彼等之方法
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
US11746149B2 (en) 2017-06-27 2023-09-05 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma
EP3645563A4 (en) 2017-06-27 2021-03-17 Neuracle Science Co., Ltd ANTI-FAM19A5 ANTIBODIES AND USES THEREOF
EP3645039A4 (en) 2017-06-27 2021-05-05 Neuracle Science Co., Ltd USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS
EP3645040A4 (en) 2017-06-27 2021-05-05 Neuracle Science Co., Ltd USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF CANCERS
ES2953032T3 (es) 2017-09-01 2023-11-07 Univ East Carolina Métodos ex vivo para la activación de las células inmunológicas
MA50175B1 (fr) 2017-09-21 2025-05-30 Neurocrine Biosciences, Inc. Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
EP3692171A4 (en) 2017-10-02 2021-06-23 Neuracle Science Co., Ltd USING ANTI-FAMILY WITH SEQUENCE LIKE 19, ELEMENT A5 ANTIBODIES FOR TREATMENT AND DIAGNOSIS OF MENTAL DISORDERS
EP3691658A4 (en) 2017-10-04 2021-06-23 The Regents of The University of California IMMUNOMODULATOR OLIGOSACCHARIDES
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
AU2017435893B2 (en) 2017-10-10 2023-06-29 Neurocrine Biosciences, Inc Methods for the administration of certain VMAT2 inhibitors
BR112020008514A2 (pt) 2017-10-31 2020-10-20 Staten Biotechnology B.V. anticorpos anti-apoc3 e métodos de uso dos mesmos
JP7395480B2 (ja) 2018-01-10 2023-12-11 クラ セラピューティクス， エルエルシー フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
WO2019139871A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
KR20200135996A (ko) 2018-03-23 2020-12-04 에이도스 테라퓨틱스, 인코포레이티드 Ag10을 사용하여 ttr 아밀로이드증을 치료하는 방법
EP3823986A4 (en) 2018-04-24 2022-03-23 Neuracle Science Co., Ltd USE OF ANTIBODIES AGAINST FAMILY SEQUENCE 19, ITEM A5 IN THE TREATMENT OF NEUROPATHIC PAIN
AU2019265888A1 (en) 2018-05-10 2020-11-26 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
WO2019241555A1 (en) 2018-06-14 2019-12-19 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
CN108533609B (zh) * 2018-06-27 2020-03-10 贵州筑信达创科技有限公司 导轨及滑动件的组合结构
CN108836091B (zh) * 2018-06-27 2020-12-04 贵州筑信达创科技有限公司 导轨
CA3105352A1 (en) 2018-06-29 2020-01-02 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
CN118994395A (zh) 2018-07-20 2024-11-22 皮埃尔法布雷医药公司 Vista受体
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
EP4647068A2 (en) 2018-08-17 2025-11-12 Eidos Therapeutics, Inc. Formulations of ag10
EP3860713A2 (en) 2018-10-03 2021-08-11 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
CN113166237B (zh) 2018-10-16 2024-11-01 纽洛可科学有限公司 抗fam19a5抗体的用途
WO2020102728A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
KR102757347B1 (ko) 2018-12-27 2025-01-23 주식회사 뉴라클사이언스 죽상경화증을 치료하기 위한 항-fam19a5 항체의 사용
JP2022515960A (ja) 2019-01-02 2022-02-24 ニューラクル サイエンス カンパニー リミテッド 抗配列類似性１９を持つファミリー、メンバーａ５抗体及びその使用方法
TWI839461B (zh) 2019-02-06 2024-04-21 美商戴斯阿爾法股份有限公司 Il-17a調節物及其用途
ES2978570T3 (es) 2019-02-26 2024-09-16 Inspirna Inc Anticuerpos anti-MERTK de alta afinidad y sus usos
ES2988904T3 (es) 2019-03-07 2024-11-22 Nobo Medicine Inc Inhibidores de caspasa y métodos de utilización de los mismos
CN119752217A (zh) 2019-05-20 2025-04-04 尼尔瓦纳科学股份有限公司 窄发射染料、包含其的组合物以及制备和使用其的方法
ES3036313T3 (en) 2019-05-20 2025-09-17 Nirvana Sciences Inc Narrow emission dyes, compositions comprising same, and methods for making and using same
EP3996813A1 (en) 2019-07-11 2022-05-18 Cura Therapeutics, LLC Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
US20220274922A1 (en) 2019-07-11 2022-09-01 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
PH12022550460A1 (en) 2019-08-30 2023-02-27 Agenus Inc Anti-cd96 antibodies and methods of use thereof
WO2021055376A1 (en) 2019-09-16 2021-03-25 Dice Alpha, Inc. Il-17a modulators and uses thereof
KR102337657B1 (ko) * 2019-11-06 2021-12-09 한국철도기술연구원 철도진동저감용 조립식 블록 및 이를 이용한 블록 구조물
JP2023512456A (ja) 2020-01-13 2023-03-27 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
CN113136745B (zh) * 2020-01-17 2024-10-25 洛阳双瑞橡塑科技有限公司 一种轨道道床吸音减振装置
WO2021151001A1 (en) 2020-01-22 2021-07-29 Outpace Bio, Inc. Chimeric polypeptides
KR20220137630A (ko) 2020-02-05 2022-10-12 워싱턴 유니버시티 Il-7 단백질과 car-보유 면역 세포의 조합물로 고형 종양을 치료하는 방법
US12006643B2 (en) * 2020-05-27 2024-06-11 Mute Wall Systems, Inc. Sound dampening barrier wall
US11529331B2 (en) 2020-05-29 2022-12-20 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
WO2021257828A1 (en) 2020-06-18 2021-12-23 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US12024521B2 (en) 2020-06-30 2024-07-02 Prosetta Biosciences, Inc. Isoquinoline derivatives, methods of synthesis and uses thereof
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202231269A (zh) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras蛋白降解劑、其醫藥組合物及其治療應用
WO2022094475A1 (en) 2020-11-02 2022-05-05 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
JP2023549112A (ja) 2020-11-05 2023-11-22 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法
CN112712784B (zh) * 2020-11-30 2024-12-31 南京华秦光声科技有限责任公司 一种低频宽带平板吸声结构
KR20230157936A (ko) 2020-12-14 2023-11-17 바이오테릭스, 인코포레이티드 Pde4 분해인자, 약제학적 조성물, 및 치료학적 적용
US20240124483A1 (en) 2021-01-27 2024-04-18 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
US20240309015A1 (en) 2021-01-27 2024-09-19 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
WO2022192545A1 (en) 2021-03-10 2022-09-15 Dice Molecules Sv, Inc. Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
WO2022226166A1 (en) 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
WO2022251533A1 (en) 2021-05-27 2022-12-01 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
JP2024520676A (ja) 2021-06-02 2024-05-24 ライエル・イミュノファーマ・インコーポレイテッド Ｎｒ４ａ３欠損免疫細胞及びその使用
IL309349A (en) 2021-06-14 2024-02-01 argenx BV Antibodies against interleukin 9 and methods of using them
CA3222240A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022266249A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2023055045A1 (ko) 2021-09-29 2023-04-06 주식회사 엔바이오스 코일드 코일 융합 단백질
CA3236150A1 (en) 2021-10-22 2023-04-27 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
US11932665B2 (en) 2022-01-03 2024-03-19 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
WO2023129576A2 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
AU2022441090A1 (en) 2022-02-17 2024-08-22 Novelty Nobility Inc. Antibody-drug conjugate.
CN118922189A (zh) 2022-03-02 2024-11-08 线粒体能量有限公司 衍生自烟酸和核糖的新型前药
WO2023192904A1 (en) 2022-03-30 2023-10-05 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
US12187699B2 (en) 2022-04-14 2025-01-07 Bristol-Myers Squibb Company GSPT1 compounds and methods of use of the novel compounds
CN119095962A (zh) 2022-05-05 2024-12-06 生物马林药物股份有限公司 治疗杜氏肌营养不良的方法
JP2025516555A (ja) 2022-05-10 2025-05-30 バイオセリックス， インコーポレイテッド Ｃｄｋタンパク質分解因子、医薬組成物、及び治療応用
EP4525892A1 (en) 2022-05-19 2025-03-26 Lyell Immunopharma, Inc. Polynucleotides targeting nr4a3 and uses thereof
IL319458A (en) 2022-09-09 2025-05-01 Innovo Therapeutics Inc Compounds that reduce ck1α and dual ck1α/gspt1
WO2024073473A1 (en) 2022-09-30 2024-04-04 Boulder Bioscience Llc Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
EP4604988A1 (en) 2022-10-21 2025-08-27 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
WO2024092040A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing bicyclic heteroaryl compounds
EP4608834A1 (en) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocycle containing pyridine compounds
US20240174672A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridone Compounds
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
WO2024118801A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
KR102870410B1 (ko) * 2022-12-09 2025-10-16 한국전자기술연구원 방음재 및 소음 제어 시스템
AU2024240129A1 (en) 2023-03-17 2025-10-09 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
AU2024252640A1 (en) 2023-04-07 2025-10-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
US20240383990A1 (en) 2023-04-07 2024-11-21 Diagonal Therapeutics Inc. Hinge-modified bispecific antibodies
WO2024226471A2 (en) 2023-04-24 2024-10-31 Biomarin Pharmaceutical Inc. Compositions and methods for treating stxbp1 disorders
TW202448485A (zh) 2023-05-05 2024-12-16 美商拜奧馬林製藥公司 肌萎縮蛋白外顯子跳躍寡核苷酸
WO2024233642A1 (en) 2023-05-09 2024-11-14 Progentos Therapeutics, Inc. Heterocyclic compounds and uses thereof
WO2024243048A1 (en) 2023-05-19 2024-11-28 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to il12 receptor
WO2025010272A1 (en) 2023-07-03 2025-01-09 Neoimmunetech, Inc. Heterodimeric fc molecules and uses thereof
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
TW202530223A (zh) 2023-09-27 2025-08-01 美商艾索司特瑞克斯公司 Ｍｙｓｔ抑制劑
WO2025085416A1 (en) 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
WO2025090519A1 (en) 2023-10-23 2025-05-01 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025147691A1 (en) 2024-01-04 2025-07-10 Innovo Therapeutics, Inc. Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025201633A1 (en) 2024-03-26 2025-10-02 Chen Gefei An agent for reducing amyloid formation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2350759A1 (de) * 1973-10-10 1975-04-24 Straetner Geb Buss Anita Abdeckplatte fuer gleisanlagen
DE3602313A1 (de) * 1986-01-27 1987-07-30 Clouth Gummiwerke Ag Schallabsorbierender laermschutz insbesondere fuer schotterlose gleise
DE4243102A1 (en) * 1991-12-20 1993-07-01 Bold Karl Gmbh & Co Noise protection and sight wall with carrier girder construction
DE29515935U1 (de) * 1995-10-07 1995-11-30 Deutsche Asphalt GmbH, 63263 Neu-Isenburg Schallabsorber für einen schotterlosen Eisenbahnoberbau
NL9400910A (nl) * 1994-06-06 1996-01-02 Veldhoen Raalte B V Samenstel voor de geluidsisolatie van een spoorbaan.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991848A (en) * 1974-08-16 1976-11-16 Frigitemp Acoustical board
US4142468A (en) * 1976-04-20 1979-03-06 Charles Birnstiel Elevated rail transit guideway with noise attenuators
US4093120A (en) 1977-01-24 1978-06-06 Park Rubber Company Railroad crossing structure
DE7711191U1 (de) 1977-04-07 1978-09-28 Straetner Geb. Buss, Anita, 4300 Essen Fahrbahnplatte fuer schienengleiche bahnuebergaenge
DE2727644C2 (de) * 1977-06-20 1983-06-30 Gummiwerk Kraiburg Elastik Gmbh & Co, 8261 Tittmoning Schienengleicher Bahnübergang
DE3827547C2 (de) * 1988-08-13 2000-09-21 Zueblin Ag Schallabsorptionskonstruktion für schotterlose Eisenbahnoberbauten
US4960184A (en) * 1989-11-09 1990-10-02 Bruce Woodward Sound absorbing structure
US5730548A (en) * 1994-02-11 1998-03-24 Autostrade-Concessioni E Costruzioni Autostrade S.P.A. Deadening road pavement and method for its realization
DE4414566C2 (de) * 1994-04-27 1997-11-20 Freudenberg Carl Fa Luftschalldämpfer
DE4417402A1 (de) 1994-05-18 1995-11-23 Gruenzweig & Hartmann Montage Schallschutzeinrichtung zur Schalldämpfung und -dämmung an Gleiskörpern
IT1293307B1 (it) * 1997-07-09 1999-02-16 Dieselbox Sa Barriera antirumore a pannelli trasparenti,dotata di caratteristiche fonoisolanti e fonoassorbenti

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2350759A1 (de) * 1973-10-10 1975-04-24 Straetner Geb Buss Anita Abdeckplatte fuer gleisanlagen
DE3602313A1 (de) * 1986-01-27 1987-07-30 Clouth Gummiwerke Ag Schallabsorbierender laermschutz insbesondere fuer schotterlose gleise
DE4243102A1 (en) * 1991-12-20 1993-07-01 Bold Karl Gmbh & Co Noise protection and sight wall with carrier girder construction
NL9400910A (nl) * 1994-06-06 1996-01-02 Veldhoen Raalte B V Samenstel voor de geluidsisolatie van een spoorbaan.
DE29515935U1 (de) * 1995-10-07 1995-11-30 Deutsche Asphalt GmbH, 63263 Neu-Isenburg Schallabsorber für einen schotterlosen Eisenbahnoberbau

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0945547A1 (de) * 1998-03-21 1999-09-29 Johann Rath Vorrichtung zur Dämpfung von Schallemissionen an Gleisanlagen
WO1999049134A1 (de) * 1998-03-21 1999-09-30 Johann Rath Vorrichtung zur dämpfung von schallemissionen an gleisanlagen
DE19812481A1 (de) * 1998-03-21 1999-09-30 Johann Rath Vorrichtung zur Dämpfung von Schallemissionen an Gleisanlagen
DE19812481C2 (de) * 1998-03-21 2002-08-22 Johann Rath Vorrichtung zur Dämpfung von Schallemissionen an Gleisanlagen
EP1039032A1 (de) * 1999-03-26 2000-09-27 DVG Deutsche Verpackungsmittel-GmbH Absorptionsbelag zur Reduzierung der Schallabstrahlung für Gleiskörper
US6481637B1 (en) * 2000-11-20 2002-11-19 Mcqueen Philip Jeffrey Rail pad and method for strain attentuation
WO2005085529A1 (de) * 2004-03-05 2005-09-15 Gmundner Fertigteile Gesellschaft M.B.H. & Co. Kg. Störschall mindernde gleiseindeckung
AU2005219446B2 (en) * 2004-03-05 2010-11-11 Gmundner Fertigteile Gesellschaft M.B.H. & Co. Kg Noise reducing track covering
NL2003697C2 (nl) * 2009-10-22 2011-04-26 Univ Twente Weg met geluid-diffractoren.
WO2011049454A2 (en) 2009-10-22 2011-04-28 Universiteit Twente Road with sound diffractors
WO2011049454A3 (en) * 2009-10-22 2012-05-18 Universiteit Twente Road with sound diffractors
US8696233B2 (en) 2009-10-22 2014-04-15 4Silence B.V. Road with sound diffractors

Also Published As

Publication number Publication date
CA2255946A1 (en) 1997-12-04
EP0901536B1 (de) 2002-12-11
TW345603B (en) 1998-11-21
ATE229595T1 (de) 2002-12-15
ES2186891T3 (es) 2003-05-16
CA2255946C (en) 2006-03-14
EP0901536A1 (de) 1999-03-17
JP3822641B2 (ja) 2006-09-20
HUP9903612A2 (hu) 2000-02-28
CN1219989A (zh) 1999-06-16
NO316078B1 (no) 2003-12-08
NO985600D0 (no) 1998-11-30
DE59708955D1 (de) 2003-01-23
HUP9903612A3 (en) 2001-08-28
AU738889B2 (en) 2001-09-27
AU2880197A (en) 1998-01-05
NO985600L (no) 1998-11-30
DK0901536T3 (da) 2003-04-07
JP2000510921A (ja) 2000-08-22
HU221872B1 (hu) 2003-02-28
CN100424268C (zh) 2008-10-08
US6253872B1 (en) 2001-07-03

Similar Documents

Publication Publication Date Title
EP0901536B1 (de) Schallschutzeinrichtung für gleise
EP0904461B1 (de) Schienengleiche eindeckung für gleise
DE2537408C3 (de) Baustein zur Herstellung einer bepflanzbaren Stützmauer
EP2817457B1 (de) Lärmschutzvorrichtung
EP0214524B1 (de) Mauerwerk- oder Pflasterstein aus Beton oder dergleichen
DE19705531A1 (de) Vorrichtung zur Überbrückung von Dehnfugen
EP0149697A1 (de) Fugenabdeckung für Dehnungsfugen in Verkehrswegen, insbesondere Brücken
DE3134473A1 (de) Schotterloser oberbau fuer schienenbahnen
DE3827547C2 (de) Schallabsorptionskonstruktion für schotterlose Eisenbahnoberbauten
DE202011052057U1 (de) Lärmschutzvorrichtung
DE4430769C2 (de) Eisenbahnoberbau mit einem auf einer durchgehenden Tragplatte aus Stahlbeton aufgelagerten Gleisrost
DE19514458A1 (de) Schallabsorbierendes Wandelement
EP2817456B1 (de) Lärmschutzvorrichtung
DE3544481A1 (de) Schallschutzwand und dafuer geeignetes wandelement
DE3727947A1 (de) Schallabsorbierendes bauelement sowie verfahren zur herstellung desselben
DE19706708A1 (de) Vorrichtung zur Schalldämpfung einer festen Fahrbahn
AT403809B (de) Schallschutzeinrichtung für gleise
EP1721045B1 (de) Störschall mindernde gleiseindeckung
DE19540357C1 (de) Eisenbahnbrücke und Kulisse zur Schalldämpfung an dieser
DE19635788A1 (de) Schalldämpfungselement für Schienentrassen mit fester Fahrbahn
EP1136622B1 (de) Gleiseindeckung
EP0166719A2 (de) Profildichtung
AT512391B1 (de) Lärmschutzvorrichtung
DE2856367A1 (de) Plattenbelag fuer daecher sowie tragelemente fuer diese
DE2607538A1 (de) Verbundformsteinelement

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97195049.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2255946

Country of ref document: CA

Ref document number: 2255946

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09194505

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1997922748

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1997 9070

Country of ref document: AT

Date of ref document: 19971204

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 19979070

Country of ref document: AT

WWP Wipo information: published in national office

Ref document number: 1997922748

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1997922748

Country of ref document: EP